{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:32:01Z","timestamp":1786649521241,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Primary pulmonary rhabdomyosarcoma (RMS) is extremely rare (0.07%) in persons aged &gt;45 years and is frequently misdiagnosed as small-cell lung cancer. Little information is available regarding the management of patients, with available literature only limited to a few case reports. We report a rare case of RMS of the lung with multiple metastases with an extensive literature review on the subject. A 52-year-old woman presented with shortness of breath, orthopnea, and chest pain for one and a half months. She also developed abdominal distension in the last month. Imaging showed a large, ill-defined solid cystic mass arising from the retroperitoneum abutting the urinary bladder with multiple adjacent small nodular deposits in serosa and peritoneum with gross ascites along with two large mass lesions in the lower lobe of the left lung and bilateral lung parenchymal metastatic deposits. The biopsy of the adnexal and lung lesions was performed along with immunohistochemistry, which was suggestive of rhabdomyosarcoma. The patient was planned for palliative chemotherapy with biweekly vincristin, adriamycin, cyclophosphamide\/ifosphamide, etoposide (VAC\/IE) regimen with prophylactic granulocyte-colony stimulating factor support followed by response assessment after 3\u20134 cycles. However, dose-compressed VAC\/IE is highly myelosuppressive and lead to febrile neutropenia in our patient and thus culminated in her death. Hence, the Indian patients should be challenged with dose-compressed VAC\/IE with extreme caution. Three-weekly IE\/VAC regimen is an alternative.<\/jats:p>","DOI":"10.4103\/jcrt.jcrt_2517_24","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T11:00:21Z","timestamp":1751713221000},"page":"762-766","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Case report of an adult with rhabdomyosarcoma of lung with ovarian metastases or the other way around: Do\u2019s and don\u2019ts with review of literature"],"prefix":"10.4103","volume":"21","author":[{"given":"Tushar","family":"Jassal","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India"},{"name":"Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipin","family":"Kharade","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saikat","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,5]]},"reference":[{"key":"R1-20250707","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/cncr.11550","article-title":"Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution","volume":"98","author":"Ferrari","year":"2003","journal-title":"Cancer"},{"key":"R2-20250707","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1631\/jzus.B1200248","article-title":"Primary pulmonary rhabdomyosarcoma in an adult:A case report and review of the literature","volume":"14","author":"Ji","year":"2013","journal-title":"J Zhejiang Univ Sci B"},{"key":"R3-20250707","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0022-3468(80)80269-7","article-title":"The intergroup rhabdomyosarcoma study II:Objectives and study design","volume":"15","author":"Maurer","year":"1980","journal-title":"J Pediatr Surg"},{"key":"R4-20250707","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s12885-024-12079-y","article-title":"Adult head and neck rhabdomyosarcoma:Radiotherapy- based treatment, outcomes, and predictors of survival","volume":"24","author":"Zhao","year":"2024","journal-title":"BMC Cancer"},{"key":"R5-20250707","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijrobp.2012.12.016","article-title":"Adult rhabdomyosarcoma survival improved with treatment on multimodality protocols","volume":"86","author":"Gerber","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R6-20250707","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/pbc.24118","article-title":"Rhabdomyosarcoma:Review of the children's oncology group (COG) soft-tissue sarcoma committee experience and rationale for current COG studies","volume":"59","author":"Malempati","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R7-20250707","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1200\/JCO.2000.18.12.2427","article-title":"Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma:Results from the intergroup rhabdomyosarcoma study IV","volume":"18","author":"Baker","year":"2000","journal-title":"J Clin Oncol"},{"key":"R8-20250707","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.2010.30.4469","article-title":"Results of the intergroup rhabdomyosarcoma study group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma:A report from the soft tissue sarcoma committee of the children's oncology group","volume":"29","author":"Raney","year":"2011","journal-title":"J Clin Oncol"},{"key":"R9-20250707","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.ijrobp.2015.08.040","article-title":"Local control for intermediate-risk rhabdomyosarcoma:Results from D9803 according to histology, group, site, and size:A report from the children's oncology group","volume":"93","author":"Wolden","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R10-20250707","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/00043426-200106000-00007","article-title":"Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma","volume":"23","author":"Weigel","year":"2001","journal-title":"J Pediatr Hematol Oncol"},{"key":"R11-20250707","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.2015.63.4048","article-title":"Intensive multiagent therapy, including dose-compressed cycles of ifosfamide\/etoposide and vincristine\/doxorubicin\/cyclophosphamide, irinotecan, and radiation, in patients with high-risk rhabdomyosarcoma:A report from the children's oncology group","volume":"34","author":"Weigel","year":"2016","journal-title":"J Clin Oncol"},{"key":"R12-20250707","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1002\/cncr.32204","article-title":"Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531:A report from the children's oncology group","volume":"125","author":"Casey","year":"2019","journal-title":"Cancer"},{"key":"R13-20250707","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/bjs.1800621024","article-title":"The importance of an innervated and intact antrum and pylorus in preventing postoperative duodenogastric reflux and gastritis","volume":"62","author":"Keighley","year":"1975","journal-title":"Br J Surg"},{"key":"R14-20250707","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1200\/JCO.2011.41.5703","article-title":"Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma:A report from the children's oncology group","volume":"30","author":"Womer","year":"2012","journal-title":"J Clin Oncol"},{"key":"R15-20250707","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1200\/JCO.2002.04.178","article-title":"2002 update of recommendations for the use of chemotherapy and radiotherapy protectants:Clinical practice guidelines of the American society of clinical oncology","volume":"20","author":"Schuchter","year":"2002","journal-title":"J Clin Oncol"},{"key":"R16-20250707","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/cncr.31770","article-title":"The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma:A report from the children's oncology group","volume":"125","author":"Malempati","year":"2019","journal-title":"Cancer"},{"issue":"(15_suppl)","key":"R17-20250707","doi-asserted-by":"crossref","first-page":"10015","DOI":"10.1200\/jco.2015.33.15_suppl.10015","article-title":"Early results from children's oncology group (COG) ARST08P1:Pilot studies of cixutumumab or temozolomide with intensive multiagent chemotherapy for patients with metastatic rhabdomyosarcoma (RMS)","volume":"33","author":"Malempati","year":"2015","journal-title":"J Clin Oncol"},{"key":"R18-20250707","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3389\/fonc.2019.01458","article-title":"Current and future treatment strategies for rhabdomyosarcoma","volume":"9","author":"Chen","year":"2019","journal-title":"Front Oncol"},{"key":"R19-20250707","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2008.21.3223","article-title":"Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma:A phase II study from the European organisation for research and treatment of cancer\u2013soft tissue and bone sarcoma group (EORTC Study 62043)","volume":"27","author":"Sleijfer","year":"2009","journal-title":"J Clin Oncol"},{"key":"R20-20250707","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE):A randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"R21-20250707","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/jjco\/hyt124","article-title":"Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent\/refractory solid tumors","volume":"43","author":"Okada","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"R22-20250707","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1002\/pbc.25548","article-title":"Phase 2 trial of sorafenib in children and young adults with refractory solid tumors:A report from the children's oncology group","volume":"62","author":"Kim","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"R23-20250707","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/OTT.S3833","article-title":"Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling","volume":"1","author":"Maruwge","year":"2008","journal-title":"Onco Targets Ther"},{"key":"R24-20250707","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejca.2018.02.011","article-title":"The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement:European organisation for research and treatment of cancer phase 2 trial 90101 'CREATE'","volume":"94","author":"Sch\u00f6ffski","year":"2018","journal-title":"Eur J Cancer"},{"key":"R25-20250707","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ejca.2011.09.021","article-title":"Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma","volume":"48","author":"Geoerger","year":"2012","journal-title":"Eur J Cancer"},{"key":"R26-20250707","doi-asserted-by":"crossref","first-page":"eaau76321","DOI":"10.1126\/scisignal.aau7632","article-title":"The HDAC3\u2013SMARCA4\u2013miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma","volume":"11","author":"Bharathy","year":"2018","journal-title":"Sci Signal"},{"key":"R27-20250707","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0749-0690(18)30746-8","article-title":"Epidemiology of osteoarthritis","volume":"4","author":"Davis","year":"1988","journal-title":"Clin Geriatr Med"},{"key":"R28-20250707","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1158\/1078-0432.CCR-15-0491","article-title":"Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors","volume":"22","author":"Merchant","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R29-20250707","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3390\/cancers12071758","article-title":"Recent advances and challenges in the treatment of rhabdomyosarcoma","volume":"12","author":"Miwa","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R30-20250707","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia:ESMO clinical practice guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann Oncol"},{"issue":"(15_suppl)","key":"R31-20250707","doi-asserted-by":"crossref","first-page":"11025","DOI":"10.1200\/JCO.2019.37.15_suppl.11025","article-title":"Interval-compressed vincristine, doxorubicin, cyclophosphamide (VAC), alternating with ifosfamide and etoposide (IE) for adults with ewing or ewing-like sarcoma","volume":"37","author":"Lu","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2517_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:54:59Z","timestamp":1786647299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2517_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_2517_24","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2024-12-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}